VivoSeq
Oncology

Localized Prostate Cancer

2

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Localized Prostate Cancer is an early-stage landscape with 2 programs across 3 companies. The most active players are Bayer, Otsuka, PROCEPT BioRobotics.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2P

PROCEPT BioRobotics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Darolutamide

Bayer

18f-Dcfpyl

University of Wisconsin, Madison

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSRadiopharmaceutical133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

4

clinical trials

Not yet recruiting2 · 50%
Recruiting2 · 50%

Clinical Trials

Trial Activity

A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer
Not yet recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT07550517·60 enrolled
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05155046·130 enrolled
CHINANEO: A China Phase 2, Open-Label, Randomized, Multicenter Study to Investigate the Efficacy and Safety of Darolutamide + ADT as Neo-Adjuvant Treatment for 12 Weeks vs 24 Weeks in Treatment-Naïve Participants Who Have Planned for Radical Prostatectomy (RP) With High-Risk Localized Prostate Cancer
Recruiting·Bayer logoBayer·Phase 2·NCT07450599·250 enrolled
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
Not yet recruiting·PPROCEPT BioRobotics·Preclinical·NCT07650448·333 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)